CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
CellaVision Dividend Announcement
• CellaVision announced a annually dividend of kr2.25 per ordinary share which will be made payable on 2024-05-13. Ex dividend date: 2024-05-06
• CellaVision annual dividend for 2024 was kr2.25
• CellaVision annual dividend for 2023 was kr2.25
• CellaVision's trailing twelve-month (TTM) dividend yield is 0.93%
• CellaVision's payout ratio for the trailing twelve months (TTM) is 35.73%
• CellaVision's dividend growth over the last five years (2018-2023) was 8.45% year
• CellaVision's dividend growth over the last ten years (2013-2023) was 18.85% year
CellaVision Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-05-06 | kr2.25 | annually | 2024-05-13 |
2023-05-08 | kr2.25 | annually | 2023-05-12 |
2022-05-12 | kr2.00 | annually | 2022-05-18 |
2021-04-30 | kr0.75 | annually | 2021-05-06 |
2020-04-24 | kr1.50 | annually | |
2019-05-09 | kr1.50 | annually | 2019-05-15 |
2018-05-07 | kr1.50 | annually | 2018-05-14 |
2017-05-08 | kr1.50 | annually | 2017-05-12 |
2016-05-06 | kr1.50 | annually | |
2015-05-07 | kr1.00 | annually | |
2014-05-08 | kr0.50 | annually | |
2013-04-25 | kr0.40 | annually |
CellaVision Dividend per year
CellaVision Dividend growth
CellaVision Dividend Yield
CellaVision current trailing twelve-month (TTM) dividend yield is 0.93%. Interested in purchasing CellaVision stock? Use our calculator to estimate your expected dividend yield:
CellaVision Financial Ratios
CellaVision Dividend FAQ
Other factors to consider when evaluating CellaVision as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy CellaVision stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: CellaVision's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, CellaVision publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, CellaVision distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from CellaVision are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: CellaVision sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, CellaVision distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: CellaVision declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of CellaVision's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review CellaVision's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.